IGF-1 vs GLP-1 Receptor Agonists: Mechanism and Class Compared

Short answer: separate peptide families, separate receptors

IGF-1 (insulin-like growth factor 1) is not a GLP-1 receptor agonist, and GLP-1 receptor agonists are not growth factors. IGF-1 is a single-chain peptide structurally homologous to proinsulin that signals at the IGF-1 receptor, a transmembrane tyrosine kinase, and sits downstream of growth hormone in the somatotropic axis. GLP-1 receptor agonists are incretin mimetics built on the glucagon-like peptide-1 sequence (or on the related exendin-4 scaffold) that bind the GLP-1 receptor, a class B G-protein-coupled receptor expressed on pancreatic beta cells, the gut, and parts of the central nervous system. The two appear together in the same clinical literature, diabetes, bone, aging, and metabolic disease, because both intersect with glucose and tissue metabolism, not because they share a target. Readers looking for background on the growth factor itself can start with the IGF-1 overview.

At a glance: how the two are described

IGF-1: origin, regulation and the growth hormone axis

IGF-1 is best understood as the effector arm of growth hormone signalling. A 2021 review of newly discovered endocrine functions of the liver described the liver as an endocrine organ releasing hormones that act on distant tissues, a framing that matters for IGF-1 because the bulk of circulating IGF-1 is hepatically produced under growth hormone stimulation (https://pubmed.ncbi.nlm.nih.gov/34904032/). Upstream of that, a 2025 review of GHRH in diabetes and metabolism examined growth hormone-releasing hormone and its analogues in metabolic disease, situating the GHRH-GH-IGF-1 axis within glucose and energy regulation (https://pubmed.ncbi.nlm.nih.gov/39560873/). The opposing inhibitory input is somatostatin: a 2013 review traced somatostatin receptor subtypes from signalling mechanisms through to clinical practice with somatostatin analogues (https://pubmed.ncbi.nlm.nih.gov/23872332/). None of these regulatory inputs involve the GLP-1 receptor.

What happens when the axis is overactive is instructive for the comparison. A 2024 review proposed an updated approach to the management of acromegaly-induced diabetes, the hyperglycaemia that can accompany states of growth hormone and IGF-1 excess (https://pubmed.ncbi.nlm.nih.gov/39738706/). That is the opposite directional signature from the one usually attributed to incretin-based agents, and it is one reason the two are not interchangeable concepts in endocrinology. IGF-1 signalling also appears in aging biology: a 2022 review of the pathobiology of the Klotho antiaging protein covered Klotho's biology and the therapeutic considerations raised by it, a field in which growth-factor and insulin-related signalling pathways are repeatedly discussed (https://pubmed.ncbi.nlm.nih.gov/35903083/).

GLP-1 receptor agonists: an incretin class

GLP-1 is an incretin hormone released from the gut after nutrient intake, and the pharmacological class takes its name from the receptor it occupies rather than from any growth-factor property. A 2005 Science STKE perspective titled "Diabetes outfoxed by GLP-1?" discussed GLP-1 signalling in the context of beta-cell biology and diabetes, illustrating how early mechanistic interest in the hormone centred on insulin-secreting cells rather than on anabolic tissue growth (https://pubmed.ncbi.nlm.nih.gov/15671479/).

Contemporary work has extended GLP-1 receptor research beyond glycaemia. A 2023 review examined the potential role of GLP-1 receptor agonists in cognitive decline and dementia in diabetes mellitus, summarising why receptor expression in the central nervous system has attracted neurological interest (https://pubmed.ncbi.nlm.nih.gov/37511061/). In preclinical work, researchers reported that pre-stroke weight loss driven by glucagon-like peptide-1 receptor and neuropeptide Y receptor Y2 activation improved post-stroke functional recovery in male diabetic mouse models (https://pubmed.ncbi.nlm.nih.gov/41094027/). On the clinical side, a 2026 review in oncology practice analysed GLP-1 receptor agonists in breast cancer, covering metabolic, clinical and survivorship implications of their use in that population (https://pubmed.ncbi.nlm.nih.gov/42385128/). Across these papers, the unifying thread is receptor occupancy at GLP-1R and its downstream metabolic consequences, not IGF-1 receptor engagement.

Where the two literatures touch

The pathways are distinct, but they are frequently discussed in the same clinical contexts. Bone is one. A 2013 review of diabetes and bone health surveyed how diabetes alters skeletal quality and fracture risk (https://pubmed.ncbi.nlm.nih.gov/23628280/), and a 2025 comprehensive review of diabetic osteoporosis revisited the pathogenesis and management of bone fragility in diabetes (https://pubmed.ncbi.nlm.nih.gov/40964165/). Growth-factor signalling and incretin signalling are both recurring themes in that field, which is part of why the two names show up side by side.

Aging and healthspan research is another meeting point. A 2026 study reported that a methionine-supplemented longevity diet increased growth hormone, GLP-1 and FGF21, reduced frailty and promoted healthspan (https://pubmed.ncbi.nlm.nih.gov/42335894/). That the study observed changes in growth hormone, the proximal driver of IGF-1, and in GLP-1 within the same intervention shows the two axes responding to shared nutritional inputs, while remaining separate hormone systems with separate receptors.

Structure, nomenclature and why the two get confused

Several naming features invite confusion. Both are peptides, both carry a hyphenated "-1", and both are discussed in metabolic medicine. Yet the structural lineages diverge entirely: IGF-1 belongs to the insulin superfamily and retains proinsulin-like architecture, whereas GLP-1 is processed from proglucagon and belongs to the glucagon/secretin peptide family. Their receptors differ at the level of class as well as sequence, a receptor tyrosine kinase that autophosphorylates and recruits intracellular adaptor proteins, versus a class B G-protein-coupled receptor that couples to intracellular second-messenger cascades. A compound engineered to bind one of these receptors would not be expected to activate the other on the basis of structural similarity.

Pharmacological engineering also differs. GLP-1 receptor agonists are designed around resistance to enzymatic degradation and extended circulating half-life so that receptor occupancy is sustained; the literature on incretin pharmacology discussed above reflects that design priority (https://pubmed.ncbi.nlm.nih.gov/15671479/). IGF-1 biology, by contrast, is dominated by binding-protein handling and by upstream GH and GHRH control, as the GHRH review described (https://pubmed.ncbi.nlm.nih.gov/39560873/).

Regulatory status

The classes also occupy different regulatory positions. Recombinant human IGF-1 (mecasermin) is an approved product for severe primary IGF-1 deficiency, a narrow endocrine indication, and growth-hormone-axis disorders are managed under specialist endocrine care. GLP-1 receptor agonists comprise a broad approved class for type 2 diabetes, with weight-management indications for certain products in certain jurisdictions. Materials sold as "research use only" peptides are not approved medicines and are not evaluated for human administration; compounded preparations are governed by separate pharmacy regulations that vary by country and state. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, medication or treatment decision.

Safety and tolerability signals in the cited papers: What Studies Report

The verified literature set summarised here was not assembled as a safety review, and it does not provide a tolerability comparison between the two classes. What it does contain are context-specific observations. The 2026 oncology review of GLP-1 receptor agonists in breast cancer examined metabolic, clinical and survivorship implications of the class in that patient population, indicating that use in people with cancer histories raises questions beyond glycaemic outcomes (https://pubmed.ncbi.nlm.nih.gov/42385128/). On the growth-factor side, the 2024 acromegaly paper addressed diabetes arising in a state of growth hormone and IGF-1 excess, which is itself a reminder that excess activity in the somatotropic axis carries metabolic consequences (https://pubmed.ncbi.nlm.nih.gov/39738706/). The stroke-recovery work was conducted in male diabetic mouse models, so its findings were reported in animals rather than people (https://pubmed.ncbi.nlm.nih.gov/41094027/).

What this literature does not establish

• No paper in this set compared IGF-1 and a GLP-1 receptor agonist head to head in the same participants.
• No paper reported that IGF-1 activates the GLP-1 receptor or that GLP-1 receptor agonists act at the IGF-1 receptor.
• Preclinical findings, such as the mouse stroke-recovery results, were reported in animals and researchers did not extend them to clinical practice (https://pubmed.ncbi.nlm.nih.gov/41094027/).
• Reviews that discussed potential roles, for example in cognition and dementia in diabetes, described potential, not established indications (https://pubmed.ncbi.nlm.nih.gov/37511061/).

For educational purposes, the practical takeaway from the pharmacology is descriptive rather than comparative: these are two distinct endocrine systems that share clinical neighbourhoods. Characterising one as a form of the other misreads both receptor biology and the structure of the published evidence.

References

• Newly discovered endocrine functions of the liver (World Journal of Hepatology, 2021)
• GHRH in diabetes and metabolism (Reviews in Endocrine & Metabolic Disorders, 2025)
• Somatostatin receptors: from signaling to clinical practice (Frontiers in Neuroendocrinology, 2013)
• Treatment of acromegaly-induced diabetes: an updated proposal (Pituitary, 2024)
• Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations (Frontiers in Aging, 2022)
• Diabetes outfoxed by GLP-1? (Science's STKE, 2005)
• Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus (International Journal of Molecular Sciences, 2023)
• Pre-stroke weight loss by glucagon-like peptide 1 receptor and neuropeptide Y receptor Y2 activation improves post-stroke functional recovery in male diabetic mouse models (Diabetologia, 2026)
• Glucagon-Like Peptide-1 Receptor Agonists in Breast Cancer: Metabolic, Clinical, and Survivorship Implications (JCO Oncology Practice, 2026)
• Diabetes and bone health (Maturitas, 2013)
• Research progress of diabetic osteoporosis: a comprehensive review (Frontiers in Endocrinology, 2025)
• Methionine-supplemented longevity diet increases growth hormone, GLP-1, and FGF21; reduces frailty; and promotes healthspan (Cell Metabolism, 2026)